Literature DB >> 11897991

Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma.

Joanna V Santeliz1, Gary Van Nest, Paula Traquina, Elizabeth Larsen, Marsha Wills-Karp.   

Abstract

BACKGROUND: Recently, it has been demonstrated that immunostimulatory DNA sequences (ISS) containing CpG motifs prevent the development of allergic airway responses in murine models of disease. However, few studies have addressed the issue of whether these agents will reverse established Tm(H)2-driven allergic airway responses.
OBJECTIVE: The aim of this study was to determine whether intradermal delivery of an immunogenic protein of ragweed pollen linked to an immunostimulatory DNA sequence could reverse an established allergic response in the mouse lung.
METHODS: Mice sensitized and challenged with ragweed pollen extract were treated intradermally twice at 1-week intervals with an ISS chemically linked to Amb a 1 (Amb a 1-ISS). One week after the Amb a 1-ISS treatment, mice were rechallenged intratracheally with ragweed extract, and airway responses were assessed.
RESULTS: Amb a 1-ISS treatment of ragweed-sensitized and ragweed-challenged mice significantly reversed allergen-induced airway hyperresponsiveness and suppressed the total number of eosinophils in bronchoalveolar lavage fluid. The inhibitory effect of Amb a 1-ISS was associated with a marked increase in IFN-gamma levels by Amb a 1-stimulated splenocytes and a shift in the antibody profile from a T(H)2-directed IgG1 response to a T(H)1-directed IgG2a response. Interestingly, the inhibitory effect of Amb a 1-ISS on allergen-driven airway hyperresponsiveness was independent of suppression of T(H)2 cytokine production.
CONCLUSION: These results demonstrate that intradermal delivery of allergen-specific DNA conjugates can reverse established allergic responses in the murine lung, supporting their potential use in the treatment of human asthma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897991     DOI: 10.1067/mai.2002.122156

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  27 in total

Review 1.  Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders.

Authors:  M Goldman
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

Review 2.  Allergen-specific pattern recognition receptor pathways.

Authors:  Marsha Wills-Karp
Journal:  Curr Opin Immunol       Date:  2010-11-17       Impact factor: 7.486

3.  Oral administration of CpG-ODNs suppresses antigen-induced asthma in mice.

Authors:  K Kitagaki; T R Businga; J N Kline
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

4.  Immunomodulatory Effects of Adjuvants CPG, MPLA, and BCG on the Derp2-Induced Acute Asthma at Early Life in an Animal Model of BALB/c Mice.

Authors:  V Mohammadi-Shahrokhi; A Rezaei; A Andalib; A Rahnama; A Jafarzadeh; N Eskandari
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

Review 5.  Adjuvants for allergy vaccines.

Authors:  Philippe Moingeon
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 6.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

7.  Reversal of established CD4+ type 2 T helper-mediated allergic airway inflammation and eosinophilia by therapeutic treatment with DNA vaccines limits progression towards chronic inflammation and remodelling.

Authors:  Elizabeth R Jarman; Jonathan R Lamb
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

Review 8.  Toll-like receptors and immune response in allergic disease.

Authors:  Sophie C Gangloff; Moncef Guenounou
Journal:  Clin Rev Allergy Immunol       Date:  2004-04       Impact factor: 8.667

9.  Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells.

Authors:  Jason D Marshall; Edith M Hessel; Josh Gregorio; Christina Abbate; Priscilla Yee; Mabel Chu; Gary Van Nest; Robert L Coffman; Karen L Fearon
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

10.  Inhibition of airway allergic disease by co-administration of flagellin with allergen.

Authors:  Shee Eun Lee; Youngil I Koh; Mi-Kwang Kim; Young Ran Kim; Soo Young Kim; Jong Hee Nam; Yoo Duk Choi; Soo Jang Bae; Young Jong Ko; Hwa-Ja Ryu; Jeong Tae Koh; Hyon E Choy; Joon Haeng Rhee
Journal:  J Clin Immunol       Date:  2007-11-17       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.